Northwestern Medicine has launched the Human Longevity Laboratory, a longitudinal, cross-sectional study that will investigate the relationship between chronological age and biological age and validate interventions that may reverse or slow down the processes of aging.
In the last several years, anti-obesity medications have made an impression through wide media coverage and interest in their effectiveness. Feinberg investigators have been leading research on these drugs for the treatment of obesity and advocating for access to these medications for the patients who need it most.
In findings published in Nature, scientists may have found a way around the limitations of engineered T-cells by borrowing a few tricks from cancer itself.
Investigators from the laboratory of Alicia Guemez-Gamboa, PhD, assistant professor of Neuroscience, have discovered new molecular mechanisms of PACS1 syndrome, a rare neurodevelopmental disorder, according to findings published in Nature Communications.
Residents are more likely to flourish in their training programs and daily lives when peer-support is strong and leadership prioritizes residents’ wellbeing, according to results from a multi-institutional survey published in Annals of Internal Medicine.
Anti-inflammatory drugs alone are not sufficient to prevent pancreas inflammation following a common endoscopic procedure, according to a study recently published in The Lancet.
A recent study from the laboratory of Joseph Bass, MD, PhD, has revealed how transcription factors within individual cells influence the identity and function of insulin-producing beta cells in the pancreas, according to findings published in Cell Metabolism.
The Pfizer BioNTech BNT162b2 vaccine was highly effective in preventing severe COVID-19 infections in children and adolescents during the Delta and Omicron variants, according to a large, national study recently published in the Annals of Internal Medicine.
A lack of cancer progression could be used as a surrogate for overall survival in newly metastatic prostate cancer clinical trials, according to a new meta-analysis published in the Journal of Clinical Oncology.
An experimental drug designed to block blood-clotting proteins may slightly lower the risk of recurrent strokes, according to a dose-finding trial published in The Lancet Neurology.